Rucaparib (AG-014699) phosphate

For research use only. Not for use in humans.

製品コードS1098 別名:PF-01367338

Rucaparib (AG-014699) phosphate化学構造

分子量(MW):421.36

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 24200 あり
JPY 21900 あり
JPY 36800 あり
JPY 113200 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(57)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明 Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
特性 The first PARP inhibitor used in clinical trials combined with temozolomide.
ターゲット
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外試験

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 NEDsb|NHfW6ldHnvckBCe3OjeR?= MmHzNE4yNzFxNUCwM|ExODBibl2= MljQbY5pcWKrdIOgVGFTWCCjY4Tpeol1gSCjdDDzeIFzfGmwZzDjc45k\XKwdILheIlwdiCxZjC1NFAhdk1? M2nJTFI2OTJ6NEW1
BT474 MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfZTJVbPTByIH7N NGfibVIyOOLCk{G1xsBl M2DTRpJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> NF\DelczPTF{OES1OS=>
SKBR3 M1Tkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPGOVAxKG6P MofRNVDjiJNzNdMg[C=> NXHaXnRtemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? M3;TblI2OTJ6NEW1
AU565 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXW[YxuPTByIH7N MV6xNQKBmzF3wrDk NWP3[Yl1emWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? M4HiUlI2OTJ6NEW1
EFM192A NI[wO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHsOVAxKG6P MWSxNQKBmzF3wrDk NYXWNolSemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? MVuyOVEzQDR3NR?=
MDA-MB-231 NXrOO49MTnWwY4Tpc44hSXO|YYm= M3TufVExNzJyL{SwJO69VQ>? MXuyOEBp NF\yWlNqdmO{ZXHz[ZMheC2DS2SgcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGHkdXozPDR{MEG1Ni=>
MDA-MB-231 MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIiyT2UxNjFvNECg{txO M3TMS|I1KGh? NVS5dnpvUUN3MPMAjV3jiIlzNz63O:Kh|ryP MnfzNlQ1OjBzNUK=
MDA-MB-231 NFzIdpRCeG:ydH;zbZMhSXO|YYm= NYnsW2ZpOTBxMkCvOFAh|ryP NWfKe2NTOjRiaB?= NVe3Wnd3cW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NFLMRmczPDR{MEG1Ni=>
MDA-MB-231 NXW3NY17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XXOVExNzJyL{SwJO69VQ>? M1LwU|I1KGh? MWTicI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvckBqdiCJMj;NJJBp[XOn MnrRNlQ1OjBzNUK=
H460 MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LxcFQxOCCwTR?= NFLWRnQzPMLiaB?= M2HBfolv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 MXiyOFQyOTZzMR?=
A549  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzMVFYzPDByIH7N M{nGXFI1yqCq MWTpcoNz\WG|ZYOgZ4VtdHWuYYKgdoFlcW:|ZX7zbZRqfmm2eR?= NUjnbmNHOjR2MUG2NVE>
DT40 M3;CbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PmXmlEPTB;MkGgcm0> M3KzdlI1OzV4OEGz
DU145 NV[0RY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfKTWM2OD1zODDuUS=> NGDpbZYzPDN3NkixNy=>
COLO704 M36wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XaTGlEPTB;Mj61NkDDuSByLk[3JO69VQ>? M{SwTlI{PzJ7NECy
OVMANAb Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTuXXB4UUN3ME2yMlU5KMLzIECuN|gh|ryP MmfZNlM4Ojl2MEK=
OV177 NHnNXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jHeGlEPTB;Mj63PEDDuSByLkexJO69VQ>? NXvLfI1qOjN5Mkm0NFI>
OAW28 NXH3TYMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHHcm9yUUN3ME2zMlYyKMLzIECuNlgh|ryP M{nhdFI{PzJ7NECy
OVSAHO NFLqT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3RVVRKSzVyPUOuOlQhyrFiMD6zN{DPxE1? M2PVc|I{PzJ7NECy
OVKATE NHrZdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwNkSgxtEhOS55OTFOwG0> NWTvb2ZCOjN5Mkm0NFI>
OVCAR3 M1XNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTNwN{SgxtEhOC52MDFOwG0> M3XpZ|I{PzJ7NECy
PEO14 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3THR2lEPTB;Mz64OEDDuSByLke2JO69VQ>? MoHnNlM4Ojl2MEK=
A2780 Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml73TWM2OD1|Lkm0JOKyKDBwMkWg{txO NWDzOoE3OjN5Mkm0NFI>
OVTOKO MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTRwMUSgxtEhOS53MzFOwG0> MkizNlM4Ojl2MEK=
KURAMOCHIb MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLyTWM2OD12LkO0JOKyKDBwMkmg{txO NHPGOFIzOzd{OUSwNi=>
TOV21G NVjwNFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTVwMEegxtEhOS5|MDFOwG0> NF;pR5gzOzd{OUSwNi=>
OVISE NVW5[pByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nHRWlEPTB;NT62PEDDuSByLkKzJO69VQ>? MmqyNlM4Ojl2MEK=
KK MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTZwMUWgxtEhOS52MjFOwG0> MmTUNlM4Ojl2MEK=
RMUGS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LJNmlEPTB;Nz6wN{DDuSBzLkizJO69VQ>? NGfaeYEzOzd{OUSwNi=>
PEO6 M2DiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\mTWM2OD15LkC2JOKyKDBwN{Sg{txO NVXhUpZEOjN5Mkm0NFI>
OVCA429 M4\ONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i5UWlEPTB;OD6yPUDDuSBzLk[0JO69VQ>? M4\lOFI{PzJ7NECy
OV167 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThwM{OgxtEhOS5zODFOwG0> NIPobnQzOzd{OUSwNi=>
RMG1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13CXWlEPTB;OT6zNkDDuSB{LkO2JO69VQ>? NXzCemFGOjN5Mkm0NFI>
OVCAR5 NGmyVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTlwNUCgxtEhOi53OTFOwG0> MkDDNlM4Ojl2MEK=
EFO21 NXjFbIx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPHTWM2OD17LkmyJOKyKDFwOEeg{txO MknQNlM4Ojl2MEK=
ES2 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDONZFKSzVyPUGwMlEzKMLzIEGuNlMh|ryP NX7IUGFQOjN5Mkm0NFI>
Tyk-nu MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GzNGlEPTB;MUCuNlAhyrFiMT6xNkDPxE1? M{XLWVI{PzJ7NECy
CAOV3 M1TuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TXbWlEPTB;MUCuN|chyrFiMD64O{DPxE1? MWOyN|czQTRyMh?=
OV207 M3;0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHCTWM2OD1zMj6yO{DDuSByLkOyJO69VQ>? MmO2NlM4Ojl2MEK=
HEY MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW3PYVMUUN3ME2xN{4xOSEEsTCwMlc2KM7:TR?= MVuyN|czQTRyMh?=
DOV13 NUC1SnNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf5OJBKSzVyPkG1JO69VQ>? M2Oy[lI{PzJ7NECy
EFO27 M3ixemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnGbHpQUUN3ME6xOUDPxE1? MnrDNlM4Ojl2MEK=
HEY C2 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRjF3IN88US=> NWPOeVlUOjN5Mkm0NFI>
KOC-7cc NFzkV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LYbmlEPTB-MUWg{txO NXrNS2JIOjN5Mkm0NFI>
MCASb MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnPTWM2OD5zNTFOwG0> NIfJdYEzOzd{OUSwNi=>
OAW42 M3jDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfWd|A2UUN3ME6xOUDPxE1? Mnz1NlM4Ojl2MEK=
OV2008 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRjF3IN88US=> NVHZe|R[OjN5Mkm0NFI>
OV90 M17nPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTQ[2lKSzVyPkG1JO69VQ>? NVPtSHdTOjN5Mkm0NFI>
OVCA420b NWHtSIhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e1OmlEPTB-MUWg{txO NGLkemgzOzd{OUSwNi=>
OVCA432 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7WTWM2OD5zNTFOwG0> NFLUPFAzOzd{OUSwNi=>
PEA2 M3O3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjQTWM2OD5zNTFOwG0> NWTOSJE2OjN5Mkm0NFI>
SKOV3 NV7xcnhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvZ[YR3UUN3ME6xOUDPxE1? M3\QRlI{PzJ7NECy
TOV112D NVP2cmNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXiNE0{KM7:TR?= MVzJR|UxRjF3IN88US=> M1vNTFI{PzJ7NECy
C4-2 M{fLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrpe40xNTNizszN NYjIWoFDOTRiZB?= NX7pWVhxTE2VTx?= NUWxcG1v\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= MoiwNlM2PjV{NES=
PC3 NGLP[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37jRlAuOyEQvF2= MWKxOEBl MXHEUXNQ MXHk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 M2nxT|I{PTZ3MkS0
DU145 NHLTRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LJb|AuOyEQvF2= MlK4NVQh\A>? NX74OlNpTE2VTx?= MkLm[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? NWjxfnFkOjN3NkWyOFQ>
VCaP  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW3NE0{KM7:TR?= NF;reVgyPCCm NGHiPIpFVVOR MlK3[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? NWrNPFJZOjN3NkWyOFQ>
LNCaP  MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHHZYQxNTNizszN NILafowyPCCm Mlz1SG1UVw>? Ml\s[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? NEjKeGUzOzV4NUK0OC=>
MDA-MB-468 NYfhSnBZS2WubDDWbYFjcWyrdImgRZN{[Xl? M3HyV2lEPTB;OT63JO69VQ>? M1;Td|IzPjd6MU[x
MDA-MB-231 M3LJbWNmdGxiVnnhZoltcXS7IFHzd4F6 Ml\OTWM2OD1zMzFOwG0> MWmyNlY4QDF4MR?=
Cal-51 MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXTJR|UxRThwNjFOwG0> NXWxOZFqOjJ4N{ixOlE>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
PAR; 

PubMed: 27960087     


MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.

BRCA1; 

PubMed: 24085845     


MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. 

27960087 24085845
Growth inhibition assay
Cell viability; 

PubMed: 31119062     


The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

31119062
Immunofluorescence
α-tubulin; 

PubMed: 30589644     


Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. 

PAR; 

PubMed: 27515310     


Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown.

γH2AX; 

PubMed: 23565244     


γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 

53BP1; 

PubMed: 23565244     


53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.

30589644 27515310 23565244
体内試験 Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

Ki Determination:

Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
細胞試験: [4]
- 合併
  • 細胞株: D425Med, D283Med and D384Med cells
  • 濃度: 0.4 μM
  • 反応時間: 3 or 5 days
  • 実験の流れ: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
    (参考用のみ)
動物試験:[4]
- 合併
  • 動物モデル: CD-1 nude mice bearing established D283Med xenografts
  • 製剤: Normal saline
  • 投薬量: 1 mg/kg
  • 投与方法: One or four daily by i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 421.36
化学式

C19H18FN3O.H3PO4

CAS No. 459868-92-9
保管
in solvent
別名 PF-01367338
Smiles CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(=CC(=C34)[NH]2)F.O[P](O)(O)=O

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03954366 Recruiting Drug: Rucaparib|Drug: Rosuvastatin|Drug: Oral Contraceptives Neoplasms Clovis Oncology Inc. May 8 2019 Phase 1
NCT03824704 Recruiting Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine May 15 2019 Phase 2
NCT03413995 Recruiting Drug: Rucaparib Prostate Cancer Metastatic Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Clovis Oncology Inc. September 10 2018 Phase 2
NCT03572478 Recruiting Drug: Rucaparib|Drug: Nivolumab Prostate Cancer|Endometrial Cancer University of Chicago|Bristol-Myers Squibb|Clovis Oncology Inc. August 14 2018 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品

Tags: Rucaparib (AG-014699) phosphateを買う | Rucaparib (AG-014699) phosphate ic50 | Rucaparib (AG-014699) phosphate供給者 | Rucaparib (AG-014699) phosphateを購入する | Rucaparib (AG-014699) phosphate費用 | Rucaparib (AG-014699) phosphate生産者 | オーダーRucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate化学構造 | Rucaparib (AG-014699) phosphate分子量 | Rucaparib (AG-014699) phosphate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID